Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Chemours crashes 35% after placing top execs on leave, Q4 report delayed

Published 02/29/2024, 09:46 AM
Updated 02/29/2024, 09:49 AM
© Reuters.  Chemours (CC) crashes 35% after placing top execs on leave, Q4 report delayed
CC
-

Shares of Chemours (CC) crashed approximately 35% at the market open on Thursday after the company announced it is putting its top executives on administrative leave amidst an internal review concerning its accounting practices.

The review, led by the board's audit committee with help from external counsel, is examining the ethics hotline reporting procedures, working capital management practices, and certain non-GAAP metrics' accuracy.

President and CEO Mark Newman, CFO Jonathan Lock, and Principal Accounting Officer Camela Wisel are the executives affected.

The probe will focus on “the processes for reviewing reports made to the Chemours Ethics Hotline, the Company’s practices for managing working capital, including the related impact on metrics within the Company’s incentive plans, certain non-GAAP metrics included in filings made with the Securities and Exchange Commission or otherwise publicly released, and related disclosures,” Chemours said in the announcement.

As a result, the chemical company had to postpone the release of its Q4 earnings report, initially scheduled for Wednesday.

Still, Chemours reported unaudited 2023 operating results with $6bn in sales, aligning closely with expectations.

Despite a net loss of $225-235 million, including significant litigation settlements and restructuring charges, the adjusted net income is estimated between $449-469 million the company said.

This surpasses both the forecasted $440 million and the consensus expectations of $437 million, suggesting a stronger Q4 than anticipated, however, CC noted it is “unsure” of its conclusions without audited formal filings.

In response to these developments, BMO Capital Markets analysts downgraded the stock to Underperform and cut the price target to $19.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

“We continue to believe many of CC's core businesses should see a recovery in 2024," analysts said.

“However, with risk to the numbers and the heightened risk tied to the abrupt management changes, we expect CC to underperform the broader Chemical sector and pull our TP to $19,” they added.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.